









Markets
/
Stocks
/
nasdaq-dsgn
/

Design Therapeutics Inc

DSGN

6.250USD

+0.300+5.04%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

355.93MMarket Cap

LossP/E TTM



Design Therapeutics Inc

6.250

+0.300+5.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

94 / 506

Overall Ranking

202 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Hold

Current Rating

7.333

Target Price

+23.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Undervalued

The company’s latest PE is -5.59, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 55.16M shares, decreasing 25.11% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 2.94M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 5.46, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.32, which is -32.35% below the recent high of -3.60 and 22.96% above the recent low of -4.10.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 6.67, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Design Therapeutics Inc is 5.00, with a high of 12.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Hold

Current Rating

7.333

Target Price

+23.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Design Therapeutics Inc

DSGN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 7.22, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 6.84 and the support level at 4.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.22

Change

1.51

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.088

Neutral

RSI(14)

60.411

Neutral

STOCH(KDJ)(9,3,3)

45.515

Neutral

ATR(14)

0.464

High Vlolatility

CCI(14)

56.022

Neutral

Williams %R

28.216

Buy

TRIX(12,20)

1.039

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

5.988

Buy

MA10

6.094

Buy

MA20

5.811

Buy

MA50

4.926

Buy

MA100

4.384

Buy

MA200

4.621

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 97.16%, representing a quarter-over-quarter decrease of 0.06%. The largest institutional shareholder is Steven Cohen, holding a total of 2.94M shares, representing 5.17% of shares outstanding, with 57.58% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ansari (Aseem Z. Ph.D.)

7.67M

SR One Capital Management, LP

6.53M

Logos Global Management LP

4.22M

Quan Venture Fund II LP

4.00M

-3.22%

Light Irrevocable Trust.

3.83M

Star Irrevocable Trust.

3.83M

Point72 Asset Management, L.P.

Star Investors

1.82M

-2.09%

BlackRock Institutional Trust Company, N.A.

2.20M

-3.21%

Frazier Life Sciences Management, L.P.

1.95M

Tang Capital Management, LLC

1.68M

+13.50%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.